AbbVie
IRB
Details
Info
21-019
AbbVie M18-868 Phase 3 Randomized, Controlled study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
